<DOC>
	<DOC>NCT00550043</DOC>
	<brief_summary>The purpose of this study is to understand the safety and tolerability of INCB018424 in patients with rheumatoid arthritis</brief_summary>
	<brief_title>A Study Exploring the Safety, Tolerability and Efficacy of a 4 Week Course of INCB018424 in Subjects With Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>1. Established diagnosis of rheumatoid arthritis 2. Patients receiving methotrexate must be treated with for at least 6 months and receiving a stable weekly dose between 10 and 25 mg for at least 8 consecutive weeks prior to study entry. 1. Patients who have taken the following drugs within the timeframe below: Leflunomide, infliximab, etanercept, adalimumab, abatacept, or other biological therapies (except rituximab) Within 12 weeks prior to the first dose of study medication; Rituximab Within 12 months prior to the first dose of study medication; Diseasemodifying antirheumatic drugs (DMARDs) or other antirheumatic therapies not specified above including but not limited to: gold, penicillamine, dapsone, azathioprine, 6mercaptopurine, chlorambucil, cyclophosphamide, cyclosporin, mycophenolate mofetil Within 12 weeks prior to the first dose of study medication; 2. Treatment with any investigational medication within 12 weeks prior to the first dose of study medication.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
</DOC>